Revolution Medicines Ships Experimental Pancreatic Drug
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Revolution Medicines began shipping its experimental pancreatic cancer drug daraxonrasib to physicians and patients under an FDA‑authorized early‑access program, CEO Mark Goldsmith announced at a STAT event.
- Food and Drug Administration authorized the early‑access program that lets the experimental drug be distributed before formal approval.
- Daraxonrasib is not yet FDA‑approved but in a Phase 3 trial patients lived nearly twice as long as those on standard chemotherapy, an unprecedented outcome for pancreatic cancer.
- The Phase 3 trial results were disclosed in mid‑April, prompting strong demand from pancreatic‑cancer patients for the therapy.
Why it matters: Pancreatic‑cancer patients gain earlier access to a therapy that doubled median survival in trial, while the FDA’s early‑access pathway speeds availability of breakthrough drugs for patients.
